Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma

• Main Authors: Ayako Ura (Author), Takuo Hayashi (Author), Kazumasa Komura (Author), Masaki Hosoya (Author), Kazuya Takamochi (Author), Eiichi Sato (Author), Satomi Saito (Author), Susumu Wakai (Author), Takafumi Handa (Author), Tsuyoshi Saito (Author), Shunsuke Kato (Author), Kenji Suzuki (Author), Takashi Yao (Author), the Tokyo Metropolitan Innovative Oncology Research Group (TMIG) (Author)
• Format: Book
• Published: Wiley, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract A limited number of patients with lung squamous cell carcinoma (SCC) benefit clinically from molecular targeted drugs because of a lack of targetable driver alterations. We aimed to understand the prevalence and clinical significance of lysine‐specific demethylase 5D (KDM5D) copy number los...